Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Increases Access to ConfirmMDx with Two Agreements

NEW YORK (GenomeWeb) – MDxHealth today announced the signing of agreements that increase the number of covered lives with access to its ConfirmMDx for Prostate Cancer test to more than 152 million in the US.

The company signed separate agreements with Ancillary Care Services, a subsidiary of American CareSource Holdings, and with Consilium, a division of preferred provider organization Devon Health Services. The agreements permit the adjudication of claims and payment for ConfirmMDx for insured patients, MDxHealth said.

ACS is an ancillary benefits and claims management firm based in Dallas covering 4.5 million lives through its managed care network agreements. Consilium, based in King of Prussia, Pa., provides solutions for out-of-network healthcare claims and reduces costs for health plans, third-party administrators, unions, and employer groups.

MDxHealth also signed deals with PPOs Galaxy Health Network and Prime Health Services in recent months providing their members access to the ConfirmMDx test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.